Syndax Pharmaceuticals Reports Inducement Grants for New Employees
Syndax Pharmaceuticals announced the grant of stock options to five new employees as an inducement for their employment.
Stocks · News reference
Syndax Pharmaceuticals Announces Acceptance of 19 Abstracts for ASH 2026 Annual Meeting
Syndax Pharmaceuticals has received notification that 19 abstracts regarding its pipeline therapies, Revuforj and Niktimvo, have been accepted for presentation at the 68th American Society of Hematology (ASH) Annual Meeting.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Syndax Pharmaceuticals to Host Investor Event at ASH 2026
Syndax Pharmaceuticals will host an in-person investor event and live webcast on December 14, 2026, during the ASH Annual Meeting.
Syndax Pharma Announces Acceptance Of Multiple Revuforj And Niktimvo Abstracts For Presentation At 68th ASH Annual Meeting
HC Wainwright & Co. Maintains Syndax Pharmaceuticals at Buy, Lowers Price Target
HC Wainwright & Co. has maintained its 'Buy' rating on Syndax Pharmaceuticals while adjusting the 12-month price target from $38 to $36.
Syndax Pharmaceuticals Reports Third Quarter 2026 Financial Results
Syndax Pharmaceuticals reported total revenue of $83.3 million for the third quarter of 2026, exceeding analyst expectations.
Syndax Pharmaceuticals Appoints Aaron A. Ondrey as Chief Financial Officer
Syndax Pharmaceuticals has named Aaron A. Ondrey as its new Chief Financial Officer, effective November 9, 2026.